French African Study Offers Critical Challenge to Generics Obstructionists By Mike Barr Railing Against Randall Tobias As if there were ever any legitimate doubt, it is now official: the three-in-one generic HAART pill ("Triomune," manufactured in India by the huge…
Pfizer Working Session in Bangkok---Invitation to Richard Stern and Dr. Stern's reply 15 June 2004 Ann Prochilo Pfizer and Company San Francisco, California Dear Ann: Thanks for this invitation [posted below this response] to participate in a forum in Bangkok…
Expert Panel's Decision to Recommend Against Routine HCV Screening Draws Community Ire By Tracy Swan "Inconsistent With Other Bodies" In March of 2004, the U.S. Prevention Services Task Force's "Screening for Hepatitis C Virus Infection in Adults: Recommendation Statement" was…
Quirky PK of BI's Tipranavir May Confine Its Use to Limited Rescue Role By Rob Camp Penned in by PK Advances in HIV pharmacology can theoretically lead to improvements in HIV care. The monitoring of antiretroviral drugs including virologic, immunologic…
Abbott, Trimeris/Roche Pricing Decisions Rekindle Old R&D Cost Questions Drug R&D Estimate (Millions) Source Invirase <$100 Interviews Norvir <$100 J. Leonard Crixivan $312* Internal memos Viracept $150 SEC docs. Agenerase <$200 SEC docs. * Goozner's estimate of Merck's total investment…
Data Error in March TAGline Issue Mike Barr or Rob Camp, In reading the latest TAGline, we noticed an error in a piece of data reported. The BMS-488043 compound was listed as being only in Phase IB when actually the…
Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation By Dr. Paul C. Bellman Whither the Checks and Balances? On April 9th, a New York City treating physician, Dr. Paul C. Bellman, submitted a treatise-length letter of protest to members of…
XI CROI, Stage for Results of Three Large HCV Treatment Trials By Tracy Swan Still No Head-to-Head Eagerly awaited results from three pivotal safety and efficacy studies of HCV treatment in HIV/HCV coinfected individuals were presented at the 11th Conference…
Vicissitudes of Medicine and Marketing Take Toll on Me-Too Line Up By Rob Camp B-I the New Salvage Outfit? Pipelines are almost as delicate and fragile as the ecosystems they go trampling through, writes TAG's Antiviral Project Director Rob Camp.…
One Shot Immune-Based Therapy Would Be Patient Dream -- and Pharma's Dread Interview with Richard Jefferys When Markets Fail In an attempt to balance last month's immune-based pipeline update, which might have been a bit heavy on cytokine therapies and…